EYENOVIA INC. - COMMO

Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

16 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device

01 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

27 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery

26 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

05 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Closing of Public Offering

23 Aug 2024 11:42:23 By Nasdaq GlobeNewswire

Eyenovia Announces Pricing of $5.14 Million Public Offering

21 Aug 2024 09:29:09 By Nasdaq GlobeNewswire

Eyenovia, Inc. Announces Proposed Public Offering

20 Aug 2024 17:09:50 By Nasdaq GlobeNewswire

Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

13 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

12 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th

08 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

07 Aug 2024 17:11:42 By Nasdaq GlobeNewswire

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

30 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

23 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Pricing of $5M Registered Direct Offering

28 Jun 2024 08:00:14 By Nasdaq GlobeNewswire

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

15 May 2024 16:01:00 By Nasdaq GlobeNewswire

Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

25 Apr 2024 07:00:01 By Nasdaq GlobeNewswire